


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Peter Prehm	Examiner: Gregg Polansky
Serial No.: 10/566,145	Group Art Unit: 1614
Filed: December 20, 2007	
For: <i>MEANS AND METHODS FOR TREATING A DISEASE WHICH IS ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN ACROSS A LIPID BILAYER</i>	Docket No.: DFM0004/US
	Confirmation No.: 9831

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

I CERTIFY THAT ON **01 APRIL 2011** THIS PAPER IS BEING
ELECTRONICALLY TRANSMITTED TO THE UNITED STATES PATENT
AND TRADEMARK OFFICE VIA THE OFFICE'S EFS-WEB


PAUL L. WEAVER

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure imposed by 37 C.F.R. § 1.56 and in accordance with the provisions of 37 C.F.R. §§ 1.97, 1.98 and MPEP 609, Applicants bring to the attention of the Examiner the following information.

Attached hereto please find Form PTO-1449 citing references submitted for consideration by the Examiner along with copies of non-U.S. patent references and non-patent references. The Examiner is respectfully requested to indicate consideration of each reference by initialing in the appropriate box for each reference, and returning an initialed copy with the next Official Action.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §102 and §103 and Applicants reserve the right, pursuant to 37 C.F.R. §1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

In accordance with 37 C.F.R. § 1.97 (b)(3), no fee is believed to be necessary for the consideration of this Information Disclosure Statement since it is being filed before the receipt of an Office action on the merits. In case the papers cross in the mail, it is requested that consideration of this Information Disclosure Statement be given under 37 C.F.R. § 1.97

Serial No. 10/566,145

Filed: December 20, 2007

For: *MEANS AND METHODS FOR TREATING A DISEASE
WHICH IS ASSOCIATED WITH AN EXCESS TRANSPORT
OF HYALURONAN ACROSS A LIPID BILAYER*

Examiner: Gregg Polansky

Group Art Unit: 1614

Docket No.: DFM0004/US

(c)(2). If any fee is required, the Office is authorized to charge Deposit Account No.

50-1775 and notify us of the same.

Respectfully Submitted,

Dated: **01 April 2011**

By: 

Paul L. Weaver, Reg. No. 48,640

Customer Number 33072

Phone: 651-275-9835

Facsimile: 651-351-2954

#60818